Product Images Bridion

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Bridion NDC 71872-7187 by Medical Purchasing Solutions, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

71872-7187-1.pdp - 71872 7187 1

71872-7187-1.pdp - 71872 7187 1

This is a description of a medication called Bridion® (Sugammadex) Injection for intravenous use only. The medication is manufactured in the Netherlands and is supplied in a single-dose vial of 2 ml, containing 200 mg/2 ml (100 mg/mL) Sugammadex. It is a sterile non-pyrogenic aqueous solution and can be stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). It should be used within five days if not protected from light. The osmolality of the product is between 300 and 500 mOsmol/kg. The usual dosage is specified in the enclosed package insert. This medication is repackaged and distributed by Medical Purchasing Solutions, Scottsdale, AZ 85260.*

Chemical Structure - bridion 01

Chemical Structure - bridion 01

Chemical Structure - bridion 02

Chemical Structure - bridion 02

Figure 1 - bridion 03

Figure 1 - bridion 03

The text describes a graph showing the median cumulative recovery times for two different drugs, sugammadex and neostigmine. The recovery times are measured in minutes and the graph also includes quartiles for sugammadex. There is a time to recovery in minutes on the X-axis and cumulative recovery rate on the Y-axis. The graph also shows product-limit estimates and mentions censored observations.*

Figure 2 - bridion 04

Figure 2 - bridion 04

This text provides information on the cumulative recovery rate for sugammadex and neostigmine as represented by their median and quartile recovery times in minutes. It also includes a graph depicting the time to recovery for the drugs. The study was conducted with vecuronium patients where 48 were treated with sugammadex and 45 were treated with neostigmine. The recovery times were estimated using product-limit estimates and include censored observations.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.